Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands.
Research and Development, AARDEX Group and Department of Public Health, University of Liège, Liege, Belgium.
Osteoporos Int. 2019 Nov;30(11):2155-2165. doi: 10.1007/s00198-019-05104-5. Epub 2019 Aug 7.
Many patients at increased risk of fractures do not take their medication appropriately, resulting in a substantial decrease in the benefits of drug therapy. Improving medication adherence is urgently needed but remains laborious, given the numerous and multidimensional reasons for non-adherence, suggesting the need for measurement-guided, multifactorial and individualized solutions.
Poor adherence to medications is a major challenge in the treatment of osteoporosis. This paper aimed to provide an overview of the consequences, determinants and potential solutions to poor adherence and persistence to osteoporosis medication.
A working group was organized by the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal diseases (ESCEO) to review consequences, determinants and potential solutions to adherence and to make recommendations for practice and further research. A systematic literature review and a face-to-face experts meeting were undertaken.
Medication non-adherence is associated with increased risk of fractures, leading to a substantial decrease in the clinical and economic benefits of drug therapy. Reasons for non-adherence are numerous and multidimensional for each patient, depending on the interplay of multiple factors, suggesting the need for multifactorial and individualized solutions. Few interventions have been shown to improve adherence or persistence to osteoporosis treatment. Promising actions include patient education with counselling, adherence monitoring with feedback and dose simplification including flexible dosing regimen. Recommendations for practice and further research were also provided. To adequately manage adherence, it is important to (1) understand the problem (initiation, implementation and/or persistence), (2) to measure adherence and (3) to identify the reason of non-adherence and fix it.
These recommendations are intended for clinicians to manage adherence of their patients and to researchers and policy makers to design, facilitate and appropriately use adherence interventions.
许多骨折风险增加的患者未能正确用药,导致药物治疗的益处显著降低。鉴于导致患者不遵医嘱的原因众多且具有多维度性,提高用药依从性迫在眉睫,但仍十分困难,这表明需要采用基于测量、多因素和个体化的解决方案。
骨质疏松症药物治疗中,患者用药依从性差是一个主要挑战。本文旨在概述骨质疏松症药物治疗中患者用药依从性和持久性差的后果、决定因素和潜在解决方案。
欧洲临床和经济骨质疏松、骨关节炎和肌肉骨骼疾病学会(ESCEO)组织了一个工作组,对依从性和持久性的后果、决定因素和潜在解决方案进行了审查,并就实践和进一步研究提出了建议。开展了系统文献回顾和一次面对面专家会议。
药物不依从与骨折风险增加相关,导致药物治疗的临床和经济效益显著降低。对于每位患者,不依从的原因因患者而异,且具有多维度性,这取决于多种因素的相互作用,表明需要采用多因素和个体化的解决方案。已证实很少有干预措施可以提高骨质疏松症治疗的依从性或持久性。有前景的措施包括患者教育加辅导、通过反馈进行依从性监测以及简化用药方案,包括采用灵活的给药方案。还提供了实践和进一步研究的建议。为了有效管理依从性,重要的是(1)了解问题(起始、实施和/或持续),(2)测量依从性,(3)确定不依从的原因并加以解决。
这些建议旨在供临床医生管理患者的依从性,供研究人员和政策制定者设计、促进和合理使用依从性干预措施。